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ABSTRACT 
 
Objective: Aim of the study was to evaluate the relationship between cortisol secretion, bone 
health and bone loss in a cohort of normal women in the early postmenopausal period.  
Methods: We measured lumbar and hip bone mineral density (BMD) by DXA and heel ultrasound 
parameters in 82 healthy, non osteoporotic (lumbar T-score ≥ -2.0) women (median age 52.5 years, 
range 42-61). These women were examined in two sessions, one year apart, in the early 
postmenopausal period (onset of menopause between 6 and 60 months). Parameters of HPA 
function were: morning serum cortisol, morning and midnight salivary cortisol, 24 hour urinary 
free cortisol (UFC), serum cortisol after 0.5 mg and 1 mg overnight dexamethasone, DHEA-S.  
Results: In multiple regression analyses, the following significant inverse correlations were found: 
1) lumbar BMD and either 24 hour UFC (p<0.005), or morning serum cortisol (p<0.005); 2) total 
femur and femoral neck BMD with morning serum cortisol (p<0.005); 3) heel ultrasound stiffness 
index and midnight salivary cortisol (p<0.005). The annual rate of change of lumbar and femoral 
BMD did not correlate with any of the above-mentioned hormonal variables. No difference was 
found in the parameters of hypothalamic pituitary adrenal (HPA)-axis function in slow (loss of BMD 
<1%) vs fast (loss of BMD ≥3%) bone losers.  
Conclusions: HPA axis may contribute to the postmenopausal bone health but differences in 
cortisol secretion do not influence the differential rate of bone loss between slow and fast bone 
losers in the early postmenopausal period, at least in healthy women.  
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INTRODUCTION 
 
Glucocorticoid induced osteoporosis (GIO) is the most common cause of secondary osteoporosis (1). 
Patients receiving exogenous glucocorticoids have a rapid increase of the risk of fragility fractures 
after the start of their therapy (2). Patients with Cushing’s syndrome, the most apparent phenotype 
of endogenous glucocorticoid excess, experience such fractures in about 50% of cases (3).  
Also patients with an incidentally discovered adrenal adenoma (adrenal incidentaloma) diagnosed 
as having subclinical hypercortisolism have been reported to display signs of GIO, including a 
reduction of bone mineral density (BMD) of the spine, altered ultrasound bone characteristics and a 
number of morphometric fractures higher than expected in the control population (4-7). A number of 
confounding factors, however, is likely to explain inconsistencies in other reports on this issue (8-10), 
prompting interest for additional studies on subtle glucocorticoid excess and bone health.  
In the last decade two papers have addressed the question whether there is an overrepresentation 
of subclinical hypercortisolism among patients with established osteoporosis. Kann et al have 
focused on impaired cortisol suppression by high-dose dexamethasone administration in 
postmenopausal osteoporotic women (11), possibly heralding a partially autonomous glucocorticoid 
secretion in a number of such cases. Chiodini et al have recently reported a surprisingly high 
prevalence of subclinical hypercortisolism in a cohort of outpatients referred for osteoporosis (12). 
The role, if any, of the endogenous glucocorticoids in the physiological bone loss after the 
menopause remains to be explored. 
More than 30 years ago, Manolagas et al explored in 18 patients the hypothesis that the wide 
variation in bone loss after surgical menopause (ovariectomy) could be attributable to differences 
in adrenal steroids (13). They found a higher urinary cortisol excretion and a paradoxically 
diminished cortisol response to corticotrophin in those women who lost bone rapidly. 
Aim of this study was to evaluate, in a cohort of healthy women without osteoporosis, in the first 
postmenopausal period, the cross-sectional relationship between measures of function of the 
hypothalamic pituitary adrenal (HPA) axis and bone health (DXA and heel ultrasound parameters) 
and to determine prospectively the relationship between the HPA axis and the rate of bone loss 
from baseline after one year. 
 
SUBJECTS AND METHODS 
 
Subjects were 82 healthy, non osteoporotic (DXA lumbar T-score ≥ -2.0) women, aged 52.3 ± 3.6 
years (mean ± SD), median 52.5 years, in the first postmenopausal state (onset of menopause 
between 6 months and 5 years). Study protocol was prepared according to the Declaration of 
Helsinki and subsequent relevant integrations and approved by the local Ethical Committee. All 
participants gave written informed consent before enrollment. The subjects were recruited among 
blood donors at the Turin section of Italian Blood Donors Association. We performed clinical 
examination and collected data about medical and drug history, current alcohol and caffeine intake, 
cigarette smoking, current physical activity and dietary calcium intake. Subjects with history of 
conditions or drug treatments (supplement of calcium and vitamin D included) known to interfere 
(in a positive or negative manner) with bone health were excluded a priori. Biochemical screening 
aimed to exclude potentially asymptomatic causes of bone loss (complete blood count, erythrocyte 
sedimentation rate, serum protein electrophoresis, serum creatinine, serum alkaline phosphatase, 
serum total calcium, serum calcium corrected for albumin levels, 24-h urinary calcium, serum 
phosphate, TSH) was obtained in all subjects. Menopausal status was confirmed by FSH, LH and 
estradiol measurements. In all participants we measured lumbar and hip bone mineral density 
(BMD), at baseline (first visit) and after 1 year (second visit), by DXA (Hologic QDR4500-W, 
Waltham, MA, USA; software version 9.03). Heel ultrasound parameters (GE Healthcare, Lunar 
Achilles Express) were obtained in 49 subjects. Markers of the HPA axis function (morning serum 
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cortisol, morning and midnight salivary cortisol, 24 hour urinary free cortisol (UFC), serum cortisol 
after 0.5 mg and 1 mg overnight dexamethasone, dehydro-epiandrosterone-sulphate (DHEA-S) 
were measured in all subjects using commercially available reagents (competitive chemilumiscent 
enzyme immunoassay by Immulite 2000 DPC, Los Angeles – USA, for serum cortisol and DHEA-S; 
radioimmunoassay by RADIM S.p.A., Pomezia (RM) – Italy, for salivary cortisol and UFC).  
A total of 92 women were screened: 9 of them were excluded a posteriori because the basal lumbar 
DXA evaluation not fulfilled the inclusion criteria of a lumbar T-score ≥-2.0 (in one case 
asymptomatic thyrotoxicosis was discovered as the main reason of reduced BMD levels) and one 
abandoned the study for familial reasons. For the remaining 82 women, follow-up data after 1 year 
were available in 80: one woman died suddenly for an acute intracerebral hemorrhage and one was 
excluded for the successive diagnosis of hyperthyroidism (while TSH levels were in the normal 
range at the time of enrollment).  
Saliva samples for the determination of midnight salivary cortisol were collected at midnight in 
commercially available devices (Salivette) using cotton swab chewed for 2–3 min and inserted into 
a double chamber plastic test tube. The saliva samples can be refrigerated at 4°C and stored at least 
for a week. Urinary and salivary samples were collected at home, conserved in fridge by the 
subjects, and delivered, the day after, at hospital.  Blood samples were drawn at hospital between 
0800 and 0900 a.m. and centrifuged at 1000 g for 15 min within 2 h of collection; sera were 
immediately frozen and stored at -20° until assayed. To avoid interference on cortisol secretion due 
to the stress of the venipuncture, an indwelling iv cannula was inserted in an antecubital vein, and 
the subjects rested inactive in a comfortable setting, at least 1 h before the withdrawal. Obviously, 
the 2400 h urine collections, the morning and midnight salivary samples and the morning serum 
cortisol samples were obtained before those on dexamethasone overnight suppression. Moreover, 
at least one week of time elapsed between the two dexamethasone tests (0.5 and 1 mg overnight). 
All assays were performed in duplicate in the same test session. Intra- and inter-assay coefficients 
of variation were in any case below 8% and 12%, respectively. Long term coefficient of variation for 
DXA instrument was 0.5% at the spine (assessed by the Hologic anthropometric spine phantom); 
short term in vivo CV were 1% and 1.5% for the lumbar spine (L1-L4) and total hip, respectively. 
Obtaining 5 repeated measurements in 3 subjects assessed the in vivo CVs for ultrasound 
parameters. The non-standardized CVs ranged from 1.2 to 2.1%. 
We performed database management and all statistical analyses using Statistica 6.0 software 
(Statsoft Inc., Tulsa, OK, USA). Normality of data was assessed by the Wilk-Shapiro test. Since the 
majority of variables showed non-normal distribution, data are presented as median with range; 
differences and correlations were analyzed by 2-tailed Mann-Whitney U-test and by multiple linear 
regression analysis Spearman R coefficient, respectively. For continuous variables we checked that 
parametric statistical analysis gave similar results. Level of statistical significance was set at p<0.05.  
 
RESULTS 
 
Demographic, clinical and data from DXA and QUS are summarized in table 1; laboratory data are 
reported in table 2. 
With regard to the cross-sectional evaluation at the first visit, a multiple regression analysis was 
initially performed including in the model each single measure of bone health separately, as 
dependent variable (i.e. BMD at lumbar spine, total femur and femoral neck; heel ultrasound 
stiffness index) and, as independent variables, all the measures of HPA function together with age, 
BMI, alcohol consumption, smoking, calcium intake, years since menopause, estimated length of 
fertility age (from menarche to menopause) and estradiol levels.  Among all the variables 
processed, only BMI and some measures of cortisol secretion (UFC, morning serum cortisol and 
midnight salivary cortisol) remained in the final models. When considering basal BMD as the 
dependent variable and BMI together with hormonal variables, as the independent ones, inverse 
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correlations were found between lumbar BMD and either 24 hour UFC and morning serum cortisol 
(R of the model =0.48, R2 =0.23, p<0.005; β for UFC=-0.32, p<0.005 and β for morning serum 
cortisol =-0.32, p<0.005). Total femur BMD resulted inversely correlated with morning serum 
cortisol (R of the model =0.47, R2 =0.22, p<0.005; β =-0.34, p<0.005); also femoral neck BMD was 
inversely correlated with morning serum cortisol (R of the model =0.42, R2 =0.17, p<0.05, β=-0.36 
p<0.005) (Figures 1 and 2). Finally, heel ultrasound stiffness index was inversely correlated with 
midnight salivary cortisol (R=0.46, R2 =0.21, p<0.05; β=-0.38, p<0.005). The strength of the above 
mentioned correlations decreases slightly removing BMI from the models, but remains statistically 
significant (Table 3). 
With regard to the second visit after one-year follow-up, when considering the annual rate of 
change of BMD, at lumbar, total femur and femoral neck site, no correlation was found with the 
hormonal variables studied. The same was true for the rate of change of heel ultrasound stiffness 
index (data not shown).  
After stratification of subjects into 2 different groups according to the percent year change of BMD 
values and using the classical definitions of “fast bone losers” (annual BMD loss ≥3%) and “slow 
bone losers” (annual BMD loss <1%) (14-16), no differences were found in any considered hormonal 
variable.  Table 4 reports evaluation of the HPA axis in the 22 fast bone losers in comparison with 
the 32 slow bone losers at lumbar spine. The absence of any significant difference was confirmed 
when analyzing the total femur and the femoral neck (data not shown).  
 
DISCUSSION 
 
The present study was designed to evaluate the influence of cortisol secretion on bone health and 
to determine whether women who lose bone rapidly in the early post-menopausal period differ 
from those who do not in measures of the HPA axis. We recruited healthy women who did not 
change lifestyle and dietary behaviors during the year of observation and we chose a lumbar DXA 
T-score of -2.0 or greater as the main inclusion criterium to avoid a compelling indication to 
treatment that may have compounded our results. Consequently, only women with normal or 
marginally decreased lumbar BMD were enrolled.  
In diverse cellular models, estrogens were found to antagonize glucocorticoid action via complex 
interference with glucocorticoid receptor function and fate (17-19). It is likely that the estrogen fall 
after menopause may allow that glucocorticoids impair bone health, even if cortisol levels are 
within the normal range. 
In agreement with this hypothesis, we found a significant inverse correlation between BMD values 
at the lumbar spine and femur with parameters of adrenal function, such as morning serum cortisol 
and urinary free cortisol. Complementary to this results, was the inverse correlation obtained 
between the heel ultrasound stiffness index and midnight salivary cortisol levels. The measurement 
of cortisol in saliva has some advantages compared to serum: it avoids the stress of venipuncture 
and estimates more precisely the free, biologically active cortisol, not being influenced by the 
salivary flux (20, 21) and variations in cortisol binding globulin (CBG) levels (21). Our data suggest that 
variations of cortisol levels within the physiological range may impair bone mass and bone quality 
in the physiological menopause. The discrepancy between serum and salivary cortisol is not easily 
understandable. Previous data reported by Dennison et al (22), who studied the circadian cortisol 
profile in 34 healthy men aged 61-72 years, are in keeping with the present findings. The negative 
relationship between cortisol levels and BMD at the lumbar and femoral sites disappeared in their 
study when BMI values were taken into account, while in our experience the relationship remains 
significant also after adjustment for BMI. Moreover, our data are in general agreement with a 
number of findings in patients with adrenal incidentalomas and subclinical hypercortisolism (4-7) 
showing that even minimal cortisol excess could exert detrimental effects on bone.  
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The adrenocortical secretion as a factor accelerating bone loss in the so called fast bone losers has 
not received adequate attention in the literature, given the difficulties of investigating subtle 
differences in the HPA axis among individuals. Even if the concept of slow and fast losers appears to 
have lost some ground in recent decades, it was a practical way to assess whether two different 
group of subjects, showing a different bone response to the fall of estrogens, are differently exposed 
to a detrimental effect of cortisol on post-menopausal bone loss. Age and time since menopause did 
not correlate in our study with the percent year change of BMD; in other words, the chance of being 
labeled as fast or slow loser was not simply related to time since the cessation of ovarian function. 
On the other hand, our data do not provide evidence that in healthy women the yearly rate of bone 
loss in the first post-menopausal period has any relationship with a number of tests exploring the 
HPA function. In our cohort, fast bone losers and slow bone losers had the same levels of the 
examined adrenal steroids in blood, saliva and urine, and the same sensitivity to dexamethasone 
inhibition. The period of one year was appropriate for stratifying the subjects in two groups of 
women who loose bone rapidly or not. Taking into account the in vitro and in vivo coefficient of 
variation for our DXA at the lumbar spine (0.5 and 1%, respectively) the least significant change 
ranged between 1,38% and 2,77%. So, also the short time interval elapsed between the 2 DXA 
measurements (just one year) can be considered adequate for detecting a BMD percent change ≥ 
3%, that reflects a real biological change.  
Our data are in agreement with those published by Manolagas et al (13) and do not support the view 
that the most abundant adrenal androgen DHEA-S has a protective role in the early 
postmenopausal bone loss. Circulating levels of DHEA-S were, in fact, superimposable in our 
women, independently of their stratification according to the rate of BMD change. At variance with 
the findings of Manolagas et al (13), we did not find differences in urinary free cortisol excretion 
between fast and slow bone losers. A possible explanation could be viewed in the different etiology 
of menopause (surgical vs physiological). It is conceivable that early menopause following 
ovariectomy is a more stressful event, in comparison with the natural cessation of ovarian function. 
Dennison et al (22) also found a link between cortisol levels and the rate of bone loss in a 4-yr follow-
up period. The longer follow-up and the gender difference could offer an explanation for this 
discrepancy. 
There are some limitations in our study. The sample size, even if not negligible, could have limited 
the statistical power of the study. The strict inclusion criteria (particularly the lumbar T-score of ≥ -
2.0) could have compromised the ability to recognize associations between bone density and 
cortisol, leading to the exclusion of subjects more likely to have abnormal cortisol levels and be fast 
bone losers.  
In summary, cortisol secretion seems to play a clear negative role on bone health in the first years 
after the menopause. Further research is worthwhile to evaluate the reasons of the subtle 
differences in otherwise physiological cortisol levels, possibly reflecting a different response of the 
HPA axis to the “stressful” event of the menopause. Conversely, differences in cortisol secretion 
assessed do not explain the differential rate of bone loss in the early post-menopausal period, at 
least in healthy, non-osteoporotic women.  
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FIGURE LEGENDS 
 
 
 
 
 
 
Figure 1. Linear correlations between lumbar bone mineral density and morning serum cortisol, on 
the left panel and between lumbar bone mineral density and 24 hour urinary cortisol (UFC), on the 
right panel. 
 
 
 
Figure 2. Linear correlations between total femur bone mineral density and morning serum cortisol, 
on the left panel and between femoral neck bone mineral density and morning serum cortisol, on the 
right panel. 
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Table 1 
 
  
Main characteristics of the subjects: demographic, clinical and densitometric data. 
 
Age, yrs  52.5 (42;61) 
Menopausal age , yrs  50 (40;59) 
Menopausal duration, yrs  2.1 (0.5;5) 
Body  mass index, Kg/m2  26.5 (19.4;38.2) 
Cigarette smoking:  never / previous / current  39(47)/31(38)/12(15) 
Moderate alcohol consumption*: yes/no 53(65)/29(35) 
Moderate caffeine consumption**: yes/no 76(93)/6(7) 
Lifestyle: active/sedentary 39(48)/43(52) 
Estimated calcium dietary intake, mg/daily 812 (350;1555) 
Lumbar spine BMD (L1-L4), g/cm2 0.938 (0.821;1.443) 
Lumbar spine T-score (L1-L4) -1.0 (-2.0;3.6) 
Lumbar spine Z-score (L1-L4) -0.1 (-1.5;4.4) 
Lumbar spine % change/yr -1.3 (-7.8;4.1) 
Total hip BMD, g/cm2 0.859 (0.659;1.108) 
Total hip T-score -0.7 (-2.3;0.7) 
Total hip Z-score -0.1 (-1.7;2.3) 
Total hip % change/yr -1.2 (-5.5;5.3) 
Femoral neck BMD, g/cm2 0.733 (0.591;0.940) 
Femoral neck T-score -1.0 (-2.3;0.8) 
Femoral neck Z-score -0.2 (-1.5;1.6) 
Femoral neck % change/yr -1.1 (-12;9.9) 
Heel ultrasound stiffness index (in 49 
subjects) 
84.5 (52;138) 
Heel ultrasound T-score (in 49 subjects) -1.2 (-3.7;2.9) 
Heel ultrasound Z-score (in 49 subjects) 0.1 (-2.4;4.3) 
Values are given as number and percentage of subjects or median and range. BMD: bone mineral 
density. 
*Moderate alcohol consumption: no more than one drink a day. 
**Moderate caffeine consumption: no more than 300 mg of caffeine a day. 
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Table 2 
 
 
Main characteristics of the subjects: laboratory data.  
 
Serum total calcium, mmol/L 2.47 (2.20-2.60) 
Serum corrected calcium, mmol/L 2.43 (2.02-2.70) 
Urinary calcium, mmol/24h 4.8 (1.9-10.2) 
Serum alkaline phoshatase, IU/L 76 (33-162) 
TSH, µIU/ml 1.76 (0.41-5.18) 
DHEA-S, µg/dl 78.9 (19.3-306) 
Morning  serum cortisol (h 8.00), µg/dl 13.8 (3.7-23.9) 
Urinary free cortisol, µg/24h 65 (35-202) 
Morning salivary cortisol (h 8.00), µg/L 10.1 (4.5-25.7) 
Midnight salivary cortisol (h 24.00), µg/L 1.0 (1.0-5.5) 
Serum cortisol after 1 mg overnight dexamethasone, µg/dl  1.0 (0.5-2.1) 
Serum cortisol after 0.5 mg overnight dexamethasone, µg/dl 1.0 (0.5-7.5) 
 
Values are given as median (range).  
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Table 3 Lumbar BMD Total femur BMD Femoral neck BMD QUS Stiffness index 
Age 
-0.04 
0.879 
  
0.45 
0.126 
0.18 
0.490 
  
0.40 
0.211 
   
-0.21 
0.575 
  
Weight 
-0.37 
0.317 
  
-0.56 
0.104 
-0.10 
0.713 
  
-0.29 
0.433 
   
-0.09 
0.808 
  
BMI 
0.75 
0.054 
0.22 
0.040 
0.21 
0.042 
0.87 
0.017 
0.36 
0.223 
  
0.54 
0.162 
0.14 
0.219 
  
0.19 
0.641 
  
YSM 
-0.10 
0.530 
  
-0.22 
0.156 
-0.16 
0.243 
  
-0.11 
0.497 
   
0.12 
0.528 
  
ELFA 
-0.12 
0.686 
  
-0.38 
0.177 
-0.17 
0.520 
  
-0.41 
0.183 
-0.09 
0.437 
  
0.08 
0.801 
  
Smoking 
-0.05 
0.682 
  
0.06 
0.609 
   
0.16 
0.210 
   
-0.16 
0.271 
  
Alcohol intake 
-0.09 
0.466 
  
-0.23 
0.06 
-0.16 
0.117 
-0.17 
0.117 
 
0.05 
0.685 
   
-0.29 
0.063 
-0.22 
0.432  
Calcium intake 
0.18 
0.159 
0.10 
0.318 
 
0.29 
0.015 
0.14 
0.210 
  
0.29 
0.024 
0.17 
0.114 
0.14 
0.190 
 
-0.21 
0.157 
-0.19 
0.236  
DHEA-S 
0.21 
0.088 
0.10 
0.338 
 
0.02 
0.803 
   
0.06 
0.634 
   
0.07 
0.633 
  
Serum F 8.00 
-0.29 
0.030 
-0.27 
0.012 
-0.26 
0.014 
-0.39 
0.002 
-0.26 
0.017 
-0.25 
0.023 
-0.21 
0.054 
-0.34 
0.011 
-0.28 
0.012 
-0.24 
0.023 
-0.25 
0.023 
-0.05 
0.744 
  
UFC 
-0.32 
0.015 
-0.32 
0.03 
-0.31 
0.004 
-0.25 
0.039 
-0.17 
0.121 
-0.14 
0.199 
 
-0.18 
0.170 
-0.12 
0.274 
  
-0.14 
0.374 
  
Salivary F 8.00 
-0.01 
0.949 
  
0.03 
0.774 
   
-0.05 
0.707 
   
-0.15 
0.369 
  
Salivary F 24.00 
-0.13 
0.290 
  
-0.12 
0.286 
   
-0.16 
0.207 
   
-0.34 
0.023 
-0.39 
0.001 
-0.35 
0.004 
F after DEX 1 mg 
-0.01 
0.953 
  
0.02 
0.819 
   
-0.01 
0.918 
   
-0.05 
0.739 
  
E2 
-0.08 
0.511 
  
-0.09 
0.430 
   
-0.07 
0.546 
   
0.01 
0.950 
  
 
Correlation matrix of the multivariate analysis. In upper lines are reported the β (r) values 
and in lower lines the p values. The step-wise multivariate models (including variables 
selected by the pre-specified criterion of p<0.2) are highlighted by a darker background. 
BMI=Body Mass Index; YSM=Years Since Menopause; ELFA=Estimated Lenght of Fertility Age; 
DHEA-S= dehydro-epiandrosterone-sulphate; F=cortisol; UFC=Urinary Free Cortisol; 
DEX=Dexamethasone; E2=Estradiol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
 
 
Table 4 
 
 
Comparison of hormonal variables in fast vs slow bone losers at lumbar spine (L1-L4) 
 
 Fast BL 
(N°=22) 
Slow BL 
(N°=32) 
Significance 
(p) 
 
Urinary free cortisol (µg/24h) 56.3 (35.4-114.7) 68.7 (35.3-118.3) 0.102 
Morning (h 8.00) serum cortisol 
(µg/dl) 
15.3 (7.4-21.9) 12.8 (9.4-21.3) 0.256 
Midnight salivary cortisol (µg/L) 2.0 (1.0-5.2) 1.0 (1.0-5.3) 0.352 
Serum cortisol after 0.5 mg overnight 
dexamethasone (µg/dl) 
1.1 (0.5-4.3) 1.1 (0.5-7.5) 0.827 
Serum cortisol after 1 mg overnight 
dexamethasone (µg/dl) 
1.0 (0.5-1.9) 1.0 (1.0-2.1) 0.917 
DHEA-S (µg/dl) 98.6 (19.3-204) 75.0 (27.3-164) 0.242 
 
Fast bone losers: annual BMD loss ≥3%; Slow bone losers: annual BMD loss <1%.  
Values are given as median and range 
 
 
 
